§ 314.101(a)(2) (or its successor regulation) that such NDA is officially “filed” or (b) with respect to an MAA, the receipt of written validation of the filing of such MAA from the EMA or acceptance or validation by the MHRA (as applicable).ġ.2 “ Accounting Standards” means, with respect to a Person, the generally accepted accounting principles as practiced in the United States (“ GAAP”), or the international standards that are promulgated by the IFRS® Foundation or its successor organization, in each case as consistently applied by such Person.ġ.3 “ Acquiring Party” has the meaning set forth in Section 2.7.2.ġ.4 “ Action” means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority.ġ.5 “ Adverse Event” has the meaning set forth in 21 C.F.R. NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the amount and sufficiency of which are hereby acknowledged, Blueprint and Clementia hereby agree as follows:Īs used in this Agreement, the following terms will have the meanings set forth below:ġ.1 “ Acceptance” means (a) with respect to an NDA, in the United States, the receipt of written notice from the FDA in accordance with 21 C.F.R. WHEREAS, the Parties desire that the activities performed under this Agreement will accelerate the development and availability of treatment options for patients suffering from FOP and other diseases.
Blueprint medicine stock price license#
WHEREAS, Clementia desires to obtain, and Blueprint desires to grant, an exclusive license under the Blueprint Product-Specific Technology and a non-exclusive license to the Blueprint Platform Technology to Exploit Blueprint Compounds and Licensed Products on the terms and conditions set forth herein and WHEREAS, Blueprint Controls Licensed Technology related to the proprietary compound known as “BLU-782” and identified on Exhibit A-1 (“ BLU-782”) and other Blueprint Compounds and has the exclusive right to grant licenses under such Licensed Technology
Blueprint and Clementia are each sometimes referred to herein as a “ Party” or collectively as the “ Parties.” Capitalized terms used but not defined in this paragraph and the Recitals below will have the meanings ascribed to such terms in Article 1 or elsewhere in this Agreement. (“ Blueprint”), and Clementia Pharmaceuticals, Inc., 1000 de la Gauchetière Street West, Suite 1200, Montreal, QC, H3B 4W5, Canada (“ Clementia”). This License Agreement (this “ Agreement”) is effective as of Octo(the “ Effective Date”), by and between Blueprint Medicines Corporation, a Delaware corporation with offices at 45 Sidney Street, Cambridge, MA, 02139 U.S.A.
0 kommentar(er)
